KYNB KYNTRA BIO INC
FollowCOM NEW (common), issuer CIK 921299
26 managers (28 13F filers) reported a position in KYNB shares at 2026-06-30, 999,150 shares in all. 1 filer opened a position and 5 filers sold out during the quarter.
- Managers
- 26
- 13F filers
- 28
- New
- 1
- Added
- 5
- Reduced
- 8
- Sold out
- 5
- Shares held by filers
- 999,150
Shares held by filers adds up every 13F filer's report, so a share reported by a parent and by its subsidiary counts twice (H9). Managers counts each filer group once.
13D and 13G filers
Each filer's latest stake. The shares are the aggregate the reporting persons state, which can include entities that file no 13F.
- ARMISTICE CAPITAL, LLC(group ARMISTICE CAPITAL, LLC)
400,000 shares, 9.88% in a 13G/A as of 2026-09-30,0001172661-26-005240
Accepted , ingested
Insider trades
| Owner | Date | Shares | Price | Filing |
|---|---|---|---|---|
| Wettig Thanedirector, officer (CEO) | 2026-11-15 | +2,500 A | $2.924 | Form 4 |
13F holders, Q2 2026
Filers in the available 13F reports with a share position at 2026-06-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.
Events
Wettig Thane acquired 2,500 KYNB shares on 2026-11-15, Form 4 filed 2026-11-17. 0001815638-26-000013
Accepted , ingestedARMISTICE CAPITAL, LLC and 1 other reporting person reported 400,000 KYNB shares, 9.88% of the class, as of 2026-09-30, in a 13G/A filed 2026-11-16. 0001172661-26-005240
Accepted , ingested